The objective of this study is to demonstrate initial safety and effectiveness of the CellFX nano-second Pulsed Field Ablation (nsPFA or nano-PFA) 360 Catheter Endocardial Ablation System in treating subjects with atrial fibrillation.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Rate of primary safety major adverse events (MAEs)
Timeframe: Within 30 days post-ablation procedure
Proportion of participants achieving acute procedural success.
Timeframe: Immediately post-ablation procedure